Clinical Trials Processing & Modality/Target Analysis

ğŸ“‘ Project Overview

This project processes clinical trial data related to specific diseases (e.g., Familial Hypercholesterolemia), enriches it with modality and biological target information, and provides structured quantitative summaries, insightful qualitative trends, and visual analytics.

Deliverables:

Functional Python notebook (âœ… ClinicalTrials_With_OpenAI_Final.ipynb)
Final enriched dataset (âœ… enriched_trials.csv)
Quantitative summary table (âœ… quantitative_summary_table.csv)
Summary visualizations (âœ… Included below and saved separately)
Qualitative insights (âœ… written and summarized)
ğŸ”¥ Key Features

Fetches studies using ClinicalTrials.gov API.
Filters studies to include only:
Interventional, Industry-sponsored, Human studies
Start dates within the last 15 years
Extracts important attributes:
Enrollment numbers, outcome measures, sponsor names, study dates, modality, and target.
Enriches intervention names dynamically using OpenAI GPT to determine Modality and Biological Target.
Generates both quantitative and qualitative summaries.
ğŸ“Š Visualizations

1. Enrollment Distribution
Shows how many patients were enrolled across trials.



2. Median Enrollment Over Time
Tracks how median patient enrollment evolved over the years.



3. Modality Trend Over Time
Tracks how the use of different therapeutic modalities has evolved.



4. Top 10 Modalities
Most frequently explored therapeutic modalities in the dataset.



5. Top 10 Biological Targets
Most commonly targeted molecules or pathways.



6. Trial Duration Distribution
Distribution of trial lengths across studies.



7. Median Trial Duration Over Time
How the length of trials has changed across years.



âœï¸ Qualitative Insights: Familial Hypercholesterolemia Clinical Trials

ğŸ”¬ Trends in Modality and Mechanism of Action:

Small molecules and monoclonal antibodies dominate the therapeutic landscape.
Behavioral therapies have been explored but remain less common.
Recent years show rising interest in gene therapies and RNA-based therapeutics (e.g., siRNA) for more targeted disease interventions.
ğŸ¯ Trends in Primary and Secondary Outcome Measures:

Early trials mainly evaluated LDL-C percentage reductions and basic lipid profile improvements.
Later studies shifted towards hard cardiovascular outcomes (e.g., heart attack incidence, mortality rates) and quality-of-life metrics.
Secondary outcomes evolved to include genetic screenings and long-term lipid regulation markers.
ğŸ“ˆ Observations on Trial Design:

Enrollment sizes have shown a declining trend, reflecting the increasing focus on targeted therapies with well-defined patient groups.
Trial durations have also become shorter, possibly due to improved regulatory pathways and accelerated therapeutic developments.
ğŸ“‚ Project Structure

ClinicalTrials_With_OpenAI_Final.ipynb  # Main Notebook
enriched_trials.csv                     # Final processed dataset
quantitative_summary_table.csv          # Quantitative metrics table
charts/                                 # Visualization PNGs
ğŸ“ˆ Technologies Used

Python (Pandas, Matplotlib, Seaborn)
OpenAI GPT (for Modality/Target enrichment)
ClinicalTrials.gov API v2
Colab Environment
